JAK2 and primary myelofibrosis: There was no statistically significant difference in LC3B-II expression depending on age, sex, origin of myelofibrosis, grade of bone marrow fibrosis, JAK2 mutational status, or Mysec-PM disease risk in SMF patients (p > 0.05 for all comparisons).